Rani Therapeutics Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RANI research report →
Range $9 – $28
Price Chart
About the company
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method.
- CEO
- Talat Imran
- IPO
- 2021
- Employees
- 70
- HQ
- San Jose, CA, US
Get TickerSpark's AI analysis on RANI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.39M
- P/E
- -2.96
- PEG
- -0.02
- P/S
- 5.55
- P/B
- 3.28
- EV/EBITDA
- -1.07
- Div Yield
- 0.00%
- Gross Margin
- 97.55%
- Op Margin
- -530.45%
- Net Margin
- -492.98%
- ROE
- -96.44%
- ROIC
- -78.48%
Latest fiscal year · YoY change
- Revenue
- $1.63M+58.9%
- Gross Profit
- $733.00K-28.7%
- Op Income
- $-38,310,000
- Net Income
- $-29,673,000+1.1%
- EPS
- $-0.45+57.1%
- OCF Growth
- +47.3%
- FCF Growth
- +47.4%
- 52W High
- $1.70
- 52W Low
- $0.50
- 50D MA
- $0.68
- 200D MA
- $0.88
- Beta
- 0.68
- RSI (14)
- 47
- Avg Volume
- 549.56K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Rani highlighted preclinical validation of its oral biologics platform in obesity, with RT-114 now the main near-term focus and cash runway into the third quarter of 2025.· March 31, 2025
- RT-116 semaglutide showed 107% relative bioavailability vs. subcutaneous dosing, with comparable weight loss and no serious adverse events in preclinical testing.
- RT-114 delivered 111% relative bioavailability vs. subcutaneous PG-102 in canines, with average peak weight loss of 6.7% and no change in drug-related safety profile.
- Management said RT-114 is the company’s primary focus for 2025 because of capital constraints and plans to move it into the clinic in mid-2025.
- Cash, cash equivalents, and marketable securities were $27.6 million at December 31, 2024, and management expects runway into the third quarter of 2025.
- Full-year 2024 losses improved versus 2023, aided by cost containment, despite a $3.7 million impairment charge in the fourth quarter.
Rani reported fourth-quarter 2024 contract revenue of approximately $1 million, versus no contract revenue in the same period of 2023. Fourth-quarter 2024 research and development expense was $6.8 million, down from $7.6 million a year ago, and full-year R&D was $26.7 million versus $39.6 million in 2023. Fourth-quarter 2024 general and administrative expense was $5.5 million, versus $5.8 million a year ago, and full-year G&A was $23.9 million versus $26.5 million in 2023. The company recorded a $3.7 million impairment loss in the fourth quarter; net loss was $15.7 million in Q4 and $56.6 million for the full year, compared with $14.1 million and $67.9 million in 2023. Cash, cash equivalents, and marketable securities were $27.6 million at December 31, 2024, down from $48.5 million a year earlier, and management said that should fund operations into the third quarter of 2025 without additional funding.
Talat Imran framed Rani as a clinical-stage platform company trying to replace painful injections with oral biologics and repeatedly emphasized the breadth of the RaniPill platform. His tone was optimistic about the obesity pipeline, especially RT-114, which he described as a potentially differentiated oral GLP-1/GLP-2 with less frequent dosing, a possible tolerability advantage, and potential lean-mass preservation. He also said the company remains open to partnering, but near-term development will be constrained by capital.
Svai Sanford focused on the reported financials and balance sheet. He said cash, cash equivalents, and marketable securities totaled $27.6 million at December 31, 2024, and that this is expected to fund operations into the third quarter of 2025. He also cited lower full-year expenses, with R&D down $12.9 million and G&A down $2.5 million versus 2023, both attributed to cost containment, while noting the $3.7 million impairment charge related to manufacturing property and equipment.
Analysts pressed on why Rani is pursuing oral semaglutide (RT-116) when the market may already have other oral GLP-1s, and management clarified RT-116 is currently a discovery program, not planned for a clinical study now. Talat Imran said RT-114 is the priority for 2025, while RT-116 may have faster potential in certain ex-U.S. markets if pursued later. Questions also focused on RT-114 tolerability, variability, and higher peak concentrations; management said oral dosing gives flexibility to slow titration or split doses if needed, and that higher peaks have not yet shown a safety signal in the canine work. On business development, management said partnering remains a priority and that there is interest in obesity, immunology, and rare disease.
The call showed tangible preclinical support for both RT-114 and RT-116, including bioavailability comparable to subcutaneous dosing and no serious adverse events in the reported studies. Management sounded confident that RT-114 could offer a differentiated obesity profile through oral delivery, weekly dosing potential, and possibly better tolerability and lean-mass preservation than existing options.
Rani is still preclinical on its main obesity programs and is cash constrained, with runway only into the third quarter of 2025. Management also acknowledged that RT-116 is not planned for clinical development right now, and that RT-114 must still prove itself in humans, including whether the higher peak exposure translates into tolerability issues.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.2%
- Shares Outstanding
- 65.32M
- Float Shares
- 47.14M
of shares held by institutions
70 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Samsara Biocapital, LLC | 10.37M | ▲ 1.87M |
| Ra Capital Management, L.P. | 8.50M | 0 |
| Awm Investment Company, Inc. | 7.50M | 0 |
| Vanguard Group Inc | 5.11M | ▲ 4.22M |
| Vanguard Capital Management LLC | 4.57M | ▲ 3.47K |
| Longaeva Partners L.P. | 2.33M | 0 |
| Polar Asset Management Partners Inc. | 2.32M | ▲ 2.32M |
| Siren, L.L.C. | 1.59M | ▼ 405.20K |
| Heights Capital Management, Inc | 934.58K | ▲ 934.58K |
| Geode Capital Management, LLC | 925.14K | ▲ 34.52K |
| Citadel Advisors LLC | 642.00K | ▲ 642.00K |
| Vanguard Fiduciary Trust Co | 547.01K | ▲ 88.88K |
Held by 37 ETFs
Biggest fund positions in RANI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 27, 26 | Imran Talat | other | 7,928 |
| Sep 27, 26 | Javadi Alireza | other | 309 |
| Aug 3, 26 | Gilson Michelle | other | 247,200 |
| Aug 1, 26 | Gilson Michelle | other | 0 |
| Jul 21, 26 | IMRAN MIR A | buy | 36,000 |
| Mar 27, 26 | Javadi Alireza | sell | 386 |
| Jun 27, 26 | Javadi Alireza | other | 309 |
| Jul 17, 26 | Imran Talat | buy | 35,000 |
| Dec 27, 24 | Imran Talat | sell | 8,014 |
| Jun 27, 25 | Imran Talat | other | 9,076 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RANI coverage
Recent articles, reports, and earnings notes.
No research on RANI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RANI report →Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
globenewswire.com · Nov 9
Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
marketbeat.com · Oct 21
Rani Therapeutics to Participate in the Chardan Healthcare Conference
globenewswire.com · Oct 13
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
globenewswire.com · Oct 5
Rani Therapeutics to Participate in Upcoming September Conferences
globenewswire.com · Sep 8
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
marketbeat.com · Aug 16
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
globenewswire.com · Aug 13
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
globenewswire.com · Aug 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.